Delcath Systems, Inc. to Participate in Oppenheimer Fall MedTech Summit on Thursday, November 12, 2020

Rhea-AI Summary

Delcath Systems announces management participation in the Oppenheimer Fall MedTech Summit on November 12, 2020, focusing on liver-directed treatments for cancer. The interventional oncology company, trading under NASDAQ symbol DCTH, is known for its investigational product, Melphalan Hydrochloride, designed for high-dose chemotherapy delivery via the Delcath Hepatic Delivery System (Melphalan/HDS). While not FDA-approved in the U.S., the system is marketed in Europe as Delcath CHEMOSAT and demonstrates ongoing efficacy studies for various liver cancers.

NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, today announced management will participate in the Oppenheimer Fall MedTech Summit on Thursday, November 12, 2020.  

Management will be available for virtual one-on-one meetings during the conference. To schedule a meeting with management, please contact your conference representative or James@HaydenIR.com. 

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) is designed to administer high-dose chemotherapy to the liver while minimizing systemic exposure and associated side effects. In addition to the Phase 3 FOCUS Trial which is evaluating the safety and efficacy of Melphalan/HDS to treat patients with hepatic-dominant ocular melanoma, we are also evaluating the potential for Melphalan/HDS to treat other forms of metastatic liver cancers. Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.

Contact:

Hayden IR
James Carbonara
(646)-755-7412
james@haydenir.com

FAQ

What is Delcath Systems' stock symbol?

Delcath Systems trades under the stock symbol DCTH on NASDAQ.

When is Delcath Systems participating in the Oppenheimer Fall MedTech Summit?

Delcath Systems will participate in the Oppenheimer Fall MedTech Summit on November 12, 2020.

What is the focus of Delcath Systems' treatment?

Delcath Systems focuses on liver-directed treatment of primary and metastatic cancers.

What is the investigational product of Delcath Systems?

The investigational product is Melphalan Hydrochloride for Injection, used with the Delcath Hepatic Delivery System.

Is Melphalan/HDS approved by the FDA?

No, Melphalan/HDS has not been approved by the U.S. Food & Drug Administration.

How is Melphalan/HDS marketed in Europe?

In Europe, it is marketed as Delcath CHEMOSAT® Hepatic Delivery System for Melphalan and has been CE Marked.